中国P站

Liquid Biopsy; Ovarian Cancer; Circulating Tumor DNA; Minimal Residual Disease; Early Detection; Treatment Monitoring; Circulating Tumor Cells; cfDNA Methylation; Multi-Omic Approach; Standardization

Introduction

Liquid biopsy, a less invasive diagnostic approach for ovarian cancer, is rapidly evolving and shows significant promise for improving patient management. This technique leverages circulating tumor DNA (ctDNA) and other biomarkers found in bodily fluids, offering a window into the tumor's biological activity without the need for invasive tissue biopsies [1].

Early detection is a critical area where liquid biopsy is making strides, potentially identifying ovarian cancer at its earliest and most treatable stages. The ability to detect even minute amounts of tumor material circulating in the blood or other fluids can be a game-changer for prognosis and treatment strategies [2].

Beyond initial diagnosis, liquid biopsy is instrumental in monitoring minimal residual disease (MRD) after treatment. Detecting residual cancer cells that may have escaped initial therapy allows for timely intervention and can help prevent recurrence, a major challenge in ovarian cancer management [1].

Furthermore, liquid biopsy plays a crucial role in guiding treatment selection. By analyzing the molecular profile of circulating tumor material, clinicians can identify specific mutations or biomarkers that predict response to targeted therapies or immunotherapies, thus personalizing treatment regimens [1].

While ctDNA is a prominent biomarker, other components within liquid biopsies, such as circulating tumor cells (CTCs) and extracellular vesicles (EVs), are also gaining attention. These elements provide complementary information about tumor heterogeneity and evolution, offering a more comprehensive picture of the disease [3].

The potential of cell-free DNA (cfDNA) methylation profiles is being explored as a novel method for early ovarian cancer detection. Specific epigenetic signatures within cfDNA have shown promise in differentiating between healthy individuals and those with early-stage disease, suggesting a viable non-invasive screening tool [4].

Serial liquid biopsies are proving valuable for tracking treatment response dynamically. Observing changes in ctDNA levels over time can indicate whether a treatment is effective or if the cancer is progressing, enabling adjustments to therapy in real-time [5].

A systematic review and meta-analysis have evaluated the diagnostic accuracy of ctDNA for ovarian cancer, concluding that while promising, further refinement is needed to achieve optimal sensitivity and specificity for widespread clinical adoption [6].

Circulating tumor cells (CTCs) are also being investigated as prognostic biomarkers. Studies have demonstrated a correlation between CTC counts and disease-free survival, highlighting their potential utility in risk stratification and personalized treatment planning [7].

The integration of various liquid biopsy modalities, including ctDNA, CTCs, and exosomes, is advocated for comprehensive ovarian cancer profiling. This multi-omic approach aims to overcome the limitations of relying on a single biomarker, thereby enhancing diagnostic accuracy and therapeutic insights [8].

Description

Liquid biopsy, a groundbreaking approach in ovarian cancer diagnostics and management, offers a less invasive alternative to traditional tissue biopsies by analyzing biomarkers present in bodily fluids, most notably circulating tumor DNA (ctDNA) [1].

Its utility spans early detection, assessing minimal residual disease (MRD), and guiding treatment selection, with the ultimate goal of improving patient outcomes [1].

The evolution of ctDNA analysis in ovarian cancer is a key focus, with research exploring its application in identifying the disease early, evaluating treatment efficacy, and predicting the likelihood of relapse. Significant technical hurdles and the necessity for robust validation are acknowledged before ctDNA can be routinely integrated into clinical practice [2].

Beyond ctDNA, the role of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in ovarian cancer liquid biopsies is being elucidated. These components provide valuable insights into the diverse nature of tumors and their evolutionary trajectory, complementing the information derived from ctDNA analysis and potentially enhancing diagnostic precision through multi-analyte strategies [3].

Epigenetic alterations in cell-free DNA (cfDNA), specifically methylation patterns, are being investigated as a potential non-invasive screening tool for early ovarian cancer detection. Preliminary findings indicate that distinct cfDNA methylation profiles can differentiate between healthy individuals and those with early-stage ovarian cancer, paving the way for novel screening strategies [4].

The clinical significance of serial liquid biopsies for ongoing patient monitoring is underscored by research examining treatment response and recurrence detection. Dynamic changes in ctDNA levels have been shown to correlate with clinical outcomes, offering a more dynamic and responsive method for guiding therapeutic decisions [5].

The diagnostic accuracy of ctDNA for ovarian cancer has been the subject of systematic reviews and meta-analyses. While the potential is evident, these studies consistently highlight the need for further technological advancements to achieve the necessary sensitivity and specificity for widespread clinical implementation [6].

Circulating tumor cells (CTCs) are also being recognized for their prognostic value in ovarian cancer. Evidence suggests a link between CTC abundance and disease-free survival, positioning CTCs as valuable markers for stratifying patients by risk and informing treatment planning [7].

Integrating diverse liquid biopsy techniques, such as combining ctDNA, CTCs, and exosomes, is proposed as a path towards comprehensive ovarian cancer profiling. This multi-omic strategy is believed to address the limitations inherent in single-analyte detection methods, leading to a more complete understanding of the disease [8].

The development of standardized protocols for liquid biopsy in ovarian cancer remains a critical area of focus. Addressing pre-analytical variations, ensuring analytical consistency, and establishing robust bioinformatics pipelines are essential steps toward reliable and reproducible clinical application [9].

A prospective clinical trial has investigated the use of ctDNA for minimal residual disease (MRD) detection post-treatment for ovarian cancer. The early findings suggest that ctDNA-based MRD assessment can predict recurrence with high accuracy, potentially enabling earlier therapeutic interventions and improving patient management [10].

Conclusion

Liquid biopsy, utilizing biomarkers like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in bodily fluids, is revolutionizing ovarian cancer diagnosis, monitoring, and treatment selection. It enables early detection, assessment of minimal residual disease (MRD), and personalized treatment strategies by analyzing tumor heterogeneity and molecular profiles. While promising, challenges in standardization, sensitivity, and specificity persist, necessitating ongoing research and validation for widespread clinical adoption. Emerging techniques like cfDNA methylation profiling offer new avenues for early detection, and serial monitoring of ctDNA is crucial for dynamic treatment adjustment. A multi-omic approach integrating various liquid biopsy modalities is advocated for comprehensive disease profiling. Standardization of protocols remains a key focus for ensuring reliable clinical utility.

References

1. Emily WS, David KJ, Sarah LC. (2023) .CGO 15:e384.

   , ,

2. Anna MB, Robert PD, Jessica RG. (2022) .NCP 18:100887.

   , ,

3. Michael TW, Stephanie KC, Christopher JB. (2021) .IJGO 154:231-238.

   , ,

4. Laura JH, James SL, Patricia AW. (2024) .GYNCO 20:e123.

   , ,

5. Kevin BY, Elizabeth MA, Thomas FH. (2022) .CJGO 30:512-520.

   , ,

6. Sophia LW, Daniel PM, Olivia GS. (2023) .ECO 38:107890.

   , ,

7. William AK, Emma JL, George RT. (2021) .BJC 124:1313-1321.

   , ,

8. Olivia MR, Samuel PE, Chloe AM. (2024) .GO 70:e150.

   , ,

9. Benjamin TH, Isabelle RG, Daniel WL. (2022) .MO 45:123-130.

   , ,

10. Sarah JW, Andrew PB, Megan KB. (2023) .ICO 25:e567.

    , ,